리노바이러스 감염증 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 8.9%의 CAGR로 19억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 항바이러스 약물에 대한 투자 증가, 표적 치료제에 대한 수요 증가, 호흡기질환의 유병률 증가, 신흥 시장에서의 의료 접근성 확대, 생물학적 제제 및 단클론항체의 사용 증가에 기인합니다. 이 기간의 주요 동향으로는 항바이러스제 연구 발전, 백신 연구 발전, 생물학적 제제 및 단클론항체 기술 혁신, 광범위 항바이러스제 개발, 약물전달을 위한 나노기술의 발전 등이 있습니다.
호흡기질환의 유병률 증가는 리노바이러스 감염증 치료제 시장의 확대를 촉진할 것으로 예상됩니다. 호흡기질환은 천식, 만성폐쇄성폐질환(COPD), 폐렴 등 폐와 기도에 영향을 미쳐 호흡을 어렵게 하는 질환입니다. 이러한 질환의 증가는 주로 대기오염의 증가와 직업적 위험에 대한 노출로 인한 것으로, 특히 취약한 집단에서 천식, COPD, 폐렴과 같은 증상의 한 원인이 되고 있습니다. 리노바이러스 감염증 치료제는 바이러스 복제를 표적으로 삼아 염증을 억제하고 증상을 완화함으로써 호흡기 건강을 지원하고 궁극적으로 호흡 기능을 개선합니다. 예를 들어, 2023년 11월 호주 국립천식위원회는 2022년 호주에서 467명의 천식 관련 사망자가 기록되어 2021년 355명에서 증가했다고 보고했습니다. 호흡기질환의 발병률이 증가함에 따라 리노바이러스 감염증 치료제에 대한 수요는 계속 증가하고 있습니다.
리노바이러스 감염증 치료제 시장의 주요 기업들은 치료 효과를 높이고, 증상의 심각성을 줄이며, 환자의 회복 속도를 높이기 위해 혁신적인 항바이러스 치료제 개발에 주력하고 있습니다. 항바이러스제는 체내 바이러스 복제를 억제하여 바이러스 감염을 치료합니다. 이 약들은 독감, HIV, 간염, 리노바이러스 등 다양한 바이러스에 효과적입니다. 항바이러스제 중에는 바이러스가 숙주 세포에 침입하는 것을 막는 것도 있고, 바이러스의 복제나 집합을 막는 것도 있습니다. 예를 들어, 2025년 3월 미국 생명공학 기업 알테사 바이오사이언스는 COPD 환자의 리노바이러스 감염증을 치료하는 경구용 광범위 항바이러스제 바펜다빌의 임상시험계획(IND) 신청을 미국 식품의약국(FDA)으로부터 승인받았습니다. 바펜다빌은 리노바이러스가 인간 세포 내로 침입하여 복제하는 것을 억제하는 방식으로 작용하며, 리노바이러스 및 기타 호흡기 엔테로바이러스의 97%에서 효능을 보였습니다. 알테사는 바펜다빌의 개발, 제조 및 상업화에 대한 전 세계 독점적 권리를 보유하고 있으며, COPD 및 천식을 포함한 고위험군 환자들에게 표적 치료제를 제공하는 것을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 리노바이러스 감염증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 리노바이러스 감염증 치료제 시장 : 성장률 분석
- 세계의 리노바이러스 감염증 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 리노바이러스 감염증 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 리노바이러스 감염증 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 리노바이러스 감염증 치료제 시장 : 제품별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 항바이러스제
- 면역조절제
- 백신
- 코 스프레이
- 대증요법
- 세계의 리노바이러스 감염증 치료제 시장 환자 연령층별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 유아
- 아동
- 성인
- 노인
- 세계의 리노바이러스 감염증 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 비강내
- 주사제
- 세계의 리노바이러스 감염증 치료제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 감기
- 천식 악화
- 만성폐쇄성폐질환(COPD) 악화
- 기타 적응증
- 세계의 리노바이러스 감염증 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 소매 약국
- 온라인 약국
- 전문 약국
- 세계의 리노바이러스 감염증 치료제 시장 항바이러스제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 플레코나릴
- 바펜다비르
- 루핀트리비르
- 기타 항바이러스제
- 세계의 리노바이러스 감염증 치료제 시장멘역 조절제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 인터페론
- 톨유사수용체 작용제
- 기타 면역조절제
- 세계의 리노바이러스 감염증 치료제 시장, 백신 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 생약독화 백신
- 불활화 백신
- 재조합 백신
- 세계의 리노바이러스 감염증 치료제 시장 코 스프레이 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 항히스타민 비강 스프레이
- 충혈 완화 비강 스프레이
- 스테로이드 비강 스프레이
- 식염수 비강 스프레이
- 세계의 리노바이러스 감염증 치료제 시장 대증요법 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 진통제
- 해열제
- 기침약
- 거담제
- 항히스타민제
제7장 지역별·국가별 분석
- 세계의 리노바이러스 감염증 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 리노바이러스 감염증 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 리노바이러스 감염증 치료제 시장 : 경쟁 구도
- 리노바이러스 감염증 치료제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- BioFire Diagnostics LLC Overview, Products and Services, Strategy and Financial Analysis
- hVIVO Services Limited Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Romark Laboratories L.C.
- Cocrystal Pharma Inc.
- Altamira Therapeutics Ltd.
- Biota Pharmaceuticals Inc.
- Aditum Bio Management Company LLC
- MetP Pharma AG
- Via Nova Therapeutics Inc.
- Maxwell Biosciences Inc.
- Altesa BioSciences Inc.
- Apollo Therapeutics Group Limited
- AIM ImmunoTech Inc.
- Bakar Labs
- Ntvirin Pharma
- bioRxiv
- Pneumagen Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 리노바이러스 감염증 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 리노바이러스 감염증 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 리노바이러스 감염증 치료제 시장 2029 : 성장 전략
제36장 부록
ksm
A rhinovirus infection drug is a pharmaceutical agent designed to prevent, treat, or manage infections caused by rhinoviruses, the primary cause of the common cold. These drugs work by inhibiting viral replication, blocking the virus's entry into host cells, or modulating the immune response to reduce symptom severity and shorten the infection's duration.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main products used for rhinovirus infections include antivirals, immunomodulators, vaccines, nasal sprays, and symptomatic treatments. Antiviral drugs specifically target the virus to reduce infection severity and duration, contributing to market growth driven by pharmaceutical advancements. These drugs are administered to various patient age groups, including infants, children, adults, and the elderly, using different routes such as oral, intranasal, and injectable. They are used for indications such as the common cold, asthma exacerbations, chronic obstructive pulmonary disease (COPD) exacerbations, and other related conditions. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.
The rhinovirus infections drug market research report is one of a series of new reports from The Business Research Company that provides rhinovirus infections drug market statistics, including the rhinovirus infections drug global market size, regional shares, competitors with the rhinovirus infections drug market share, detailed rhinovirus infections drug market segments, market trends, and opportunities, and any further data you may need to thrive in the rhinovirus infections drug. This rhinovirus infections drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The rhinovirus infections drug market size has grown strongly in recent years. It will grow from $1.26 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historic period can be attributed to the increasing prevalence of the common cold, greater awareness about respiratory infections, rising demand for over-the-counter medications, higher healthcare expenditure, and the growing adoption of combination therapies.
The rhinovirus infections drug market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth projected during the forecast period can be attributed to rising investments in antiviral drugs, a growing demand for targeted therapies, an increasing prevalence of respiratory disorders, expanding healthcare access in emerging markets, and the rising use of biologics and monoclonal antibodies. Key trends during this period include advancements in antiviral research, progress in vaccine research, innovation in biologics and monoclonal antibodies, the development of broad-spectrum antivirals, and advancements in nanotechnology for drug delivery.
The growing prevalence of respiratory disorders is anticipated to drive the expansion of the rhinovirus infections drug market. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The rise in these disorders is mainly due to increased air pollution and exposure to occupational hazards, which contribute to conditions such as asthma, COPD, and pneumonia, particularly in vulnerable populations. Rhinovirus infection drugs support respiratory health by targeting viral replication, reducing inflammation, and alleviating symptoms, ultimately improving respiratory function. For example, in November 2023, the National Asthma Council of Australia reported that in 2022, Australia recorded 467 asthma-related deaths, an increase from 355 deaths in 2021. As the incidence of respiratory disorders rises, the demand for rhinovirus infections drugs continues to grow.
Leading companies in the rhinovirus infections drug market are focused on developing innovative antiviral treatments to improve treatment effectiveness, lessen symptom severity, and speed up recovery for patients. Antiviral drugs treat viral infections by inhibiting the replication of viruses within the body. These drugs are effective against a range of viruses, including influenza, HIV, hepatitis, and rhinovirus. Some antivirals prevent the virus from entering host cells, while others block viral replication or assembly. For instance, in March 2025, Altesa BioSciences Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir, an oral broad-spectrum antiviral to treat rhinovirus infections in individuals with COPD. Vapendavir works by preventing the rhinovirus from entering and replicating in human cells and has shown effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa holds exclusive global rights to develop, manufacture, and commercialize vapendavir, aiming to provide targeted treatment for high-risk populations, including those with COPD and asthma.
In September 2022, RIGImmune Inc., a US-based preclinical-stage biopharmaceutical company, acquired Subintro for an undisclosed amount. This acquisition enhances RIGImmune's development of stem-loop RNA therapeutics (SLRs), designed to activate the RIG-I innate immune sensor, which may improve the treatment and prevention of viral respiratory diseases. Subintro, a UK-based biotechnology company, specializes in antiviral therapeutics targeting respiratory diseases caused by RNA viruses, such as influenza, RSV, rhinovirus, and SARS-CoV-2.
Major players in the rhinovirus infections drug market are Pfizer Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., BioFire Diagnostics LLC, hVIVO Services Limited, Romark Laboratories L.C., Cocrystal Pharma Inc., Altamira Therapeutics Ltd., Biota Pharmaceuticals Inc., Aditum Bio Management Company LLC, MetP Pharma AG, Via Nova Therapeutics Inc., Maxwell Biosciences Inc., Altesa BioSciences Inc., Apollo Therapeutics Group Limited, AIM ImmunoTech Inc., Bakar Labs, Ntvirin Pharma, bioRxiv, Pneumagen Ltd.
North America was the largest region in the rhinovirus infection drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhinovirus infections drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rhinovirus infections drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rhinovirus infections drug market consists of sales of decongestants, antihistamines, and pain relievers and fever reducers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rhinovirus Infections Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rhinovirus infections drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rhinovirus infections drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rhinovirus infections drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Antivirals; Immunomodulators; Vaccines; Nasal Sprays; Symptomatic Treatments
- 2) By Patient Age Group: Infants; Children; Adults; Elderly
- 3) By Route Of Administration: Oral; Intranasal; Injectable
- 4) By Indication: Common Cold; Asthma Exacerbation; Chronic Obstructive Pulmonary Disease (COPD) Exacerbation; Other Indications
- 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
- Subsegments:
- 1) By Antivirals: Pleconaril; Vapendavir; Rupintrivir; Other Antivirals
- 2) By Immunomodulators: Interferons; Toll-Like Receptor Agonists; Other Immunomodulators
- 3) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Recombinant Vaccines
- 4) By Nasal Sprays: Antihistamine Nasal Sprays; Decongestant Nasal Sprays; Steroid Nasal Sprays; Saline Nasal Sprays
- 5) By Symptomatic Treatments: Analgesics; Antipyretics; Cough Suppressants; Expectorants; Antihistamines
- Companies Mentioned: Pfizer Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; BioFire Diagnostics LLC; hVIVO Services Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Rhinovirus Infections Drug Market Characteristics
3. Rhinovirus Infections Drug Market Trends And Strategies
4. Rhinovirus Infections Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Rhinovirus Infections Drug Growth Analysis And Strategic Analysis Framework
- 5.1. Global Rhinovirus Infections Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Rhinovirus Infections Drug Market Growth Rate Analysis
- 5.4. Global Rhinovirus Infections Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Rhinovirus Infections Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Rhinovirus Infections Drug Total Addressable Market (TAM)
6. Rhinovirus Infections Drug Market Segmentation
- 6.1. Global Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antivirals
- Immunomodulators
- Vaccines
- Nasal Sprays
- Symptomatic Treatments
- 6.2. Global Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Infants
- Children
- Adults
- Elderly
- 6.3. Global Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intranasal
- Injectable
- 6.4. Global Rhinovirus Infections Drug Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Common Cold
- Asthma Exacerbation
- Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
- Other Indications
- 6.5. Global Rhinovirus Infections Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
- 6.6. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pleconaril
- Vapendavir
- Rupintrivir
- Other Antivirals
- 6.7. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Interferons
- Toll-like Receptor Agonists
- Other Immunomodulators
- 6.8. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Live Attenuated Vaccines
- Inactivated Vaccines
- Recombinant Vaccines
- 6.9. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Nasal Sprays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antihistamine Nasal Sprays
- Decongestant Nasal Sprays
- Steroid Nasal Sprays
- Saline Nasal Sprays
- 6.10. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Analgesics
- Antipyretics
- Cough Suppressants
- Expectorants
- Antihistamines
7. Rhinovirus Infections Drug Market Regional And Country Analysis
- 7.1. Global Rhinovirus Infections Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Rhinovirus Infections Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Rhinovirus Infections Drug Market
- 8.1. Asia-Pacific Rhinovirus Infections Drug Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Rhinovirus Infections Drug Market
- 9.1. China Rhinovirus Infections Drug Market Overview
- 9.2. China Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Rhinovirus Infections Drug Market
- 10.1. India Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Rhinovirus Infections Drug Market
- 11.1. Japan Rhinovirus Infections Drug Market Overview
- 11.2. Japan Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Rhinovirus Infections Drug Market
- 12.1. Australia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Rhinovirus Infections Drug Market
- 13.1. Indonesia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Rhinovirus Infections Drug Market
- 14.1. South Korea Rhinovirus Infections Drug Market Overview
- 14.2. South Korea Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Rhinovirus Infections Drug Market
- 15.1. Western Europe Rhinovirus Infections Drug Market Overview
- 15.2. Western Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Rhinovirus Infections Drug Market
- 16.1. UK Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Rhinovirus Infections Drug Market
- 17.1. Germany Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Rhinovirus Infections Drug Market
- 18.1. France Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Rhinovirus Infections Drug Market
- 19.1. Italy Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Rhinovirus Infections Drug Market
- 20.1. Spain Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Rhinovirus Infections Drug Market
- 21.1. Eastern Europe Rhinovirus Infections Drug Market Overview
- 21.2. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Rhinovirus Infections Drug Market
- 22.1. Russia Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Rhinovirus Infections Drug Market
- 23.1. North America Rhinovirus Infections Drug Market Overview
- 23.2. North America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Rhinovirus Infections Drug Market
- 24.1. USA Rhinovirus Infections Drug Market Overview
- 24.2. USA Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Rhinovirus Infections Drug Market
- 25.1. Canada Rhinovirus Infections Drug Market Overview
- 25.2. Canada Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Rhinovirus Infections Drug Market
- 26.1. South America Rhinovirus Infections Drug Market Overview
- 26.2. South America Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Rhinovirus Infections Drug Market
- 27.1. Brazil Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Rhinovirus Infections Drug Market
- 28.1. Middle East Rhinovirus Infections Drug Market Overview
- 28.2. Middle East Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Rhinovirus Infections Drug Market
- 29.1. Africa Rhinovirus Infections Drug Market Overview
- 29.2. Africa Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Rhinovirus Infections Drug Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Rhinovirus Infections Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Rhinovirus Infections Drug Market Competitive Landscape And Company Profiles
- 30.1. Rhinovirus Infections Drug Market Competitive Landscape
- 30.2. Rhinovirus Infections Drug Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. BioFire Diagnostics LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. hVIVO Services Limited Overview, Products and Services, Strategy and Financial Analysis
31. Rhinovirus Infections Drug Market Other Major And Innovative Companies
- 31.1. Romark Laboratories L.C.
- 31.2. Cocrystal Pharma Inc.
- 31.3. Altamira Therapeutics Ltd.
- 31.4. Biota Pharmaceuticals Inc.
- 31.5. Aditum Bio Management Company LLC
- 31.6. MetP Pharma AG
- 31.7. Via Nova Therapeutics Inc.
- 31.8. Maxwell Biosciences Inc.
- 31.9. Altesa BioSciences Inc.
- 31.10. Apollo Therapeutics Group Limited
- 31.11. AIM ImmunoTech Inc.
- 31.12. Bakar Labs
- 31.13. Ntvirin Pharma
- 31.14. bioRxiv
- 31.15. Pneumagen Ltd.
32. Global Rhinovirus Infections Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Rhinovirus Infections Drug Market
34. Recent Developments In The Rhinovirus Infections Drug Market
35. Rhinovirus Infections Drug Market High Potential Countries, Segments and Strategies
- 35.1 Rhinovirus Infections Drug Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Rhinovirus Infections Drug Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Rhinovirus Infections Drug Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34955_Rhinovirus_Infections_Drug_GMR_2025
